These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38307392)

  • 1. Clinical pharmacokinetics and drug-drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective.
    Cheng F; Wang H; Li W; Zhang Y
    Crit Rev Oncol Hematol; 2024 Mar; 195():104258. PubMed ID: 38307392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.
    van Leeuwen RW; van Gelder T; Mathijssen RH; Jansman FG
    Lancet Oncol; 2014 Jul; 15(8):e315-26. PubMed ID: 24988935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations.
    Reff MJ; Shillingburg A; Shah B; Elder C; Prescott H; Kennerly-Shah J
    J Oncol Pharm Pract; 2020 Jan; 26(1):156-174. PubMed ID: 31354102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
    Lee H; Basso IN; Kim DDH
    Int J Hematol; 2021 May; 113(5):632-641. PubMed ID: 33772728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Cuellar S; Vozniak M; Rhodes J; Forcello N; Olszta D
    J Oncol Pharm Pract; 2018 Sep; 24(6):433-452. PubMed ID: 28580869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy.
    Wang R; Zhong C; Zhang C; Hua M; Ma D
    Curr Drug Metab; 2017; 18(3):199-206. PubMed ID: 28093990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
    Atallah E; Schiffer CA; Weinfurt KP; Zhang MJ; Radich JP; Oehler VG; Pinilla-Ibarz J; Deininger MWN; Lin L; Larson RA; Mauro MJ; Moore JO; Ritchie EK; Shah NP; Silver RT; Wadleigh M; Cortes J; Thompson J; Guhl J; Horowitz MM; Flynn KE
    BMC Cancer; 2018 Apr; 18(1):359. PubMed ID: 29609532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
    Shoukier M; Kubiak M; Cortes J
    Curr Oncol Rep; 2021 Jun; 23(8):91. PubMed ID: 34125316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors.
    Xu XL; Cao YJ; Zhang W; Rao GW
    Curr Med Chem; 2022; 29(17):3050-3078. PubMed ID: 34636293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.
    Kumar V; Singh P; Gupta SK; Ali V; Verma M
    Mol Cell Biochem; 2022 Apr; 477(4):1261-1279. PubMed ID: 35129779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors.
    Kondapalli L; Worth S; Hawi R; Vachhani P; Arora G; Bhatia R; Lenneman CG
    Vasc Med; 2020 Jun; 25(3):246-254. PubMed ID: 32303152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Research Advance of
    Zhou LY; Zhou LY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):585-588. PubMed ID: 37096538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Jabbour E; Branford S; Saglio G; Jones D; Cortes JE; Kantarjian HM
    Cancer; 2011 May; 117(9):1800-11. PubMed ID: 21509757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adverse events of ABL tyrosine kinase inhibitors in chronic myeloid leukemia therapy].
    Tauchi T
    Rinsho Ketsueki; 2018; 59(10):2089-2093. PubMed ID: 30305513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option.
    Lipton JH; Brümmendorf TH; Gambacorti-Passerini C; Garcia-Gutiérrez V; Deininger MW; Cortes JE
    Blood Rev; 2022 Nov; 56():100968. PubMed ID: 35570071
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Kc R; Thapa B; Ubeda A; Jiang X; Uludağ H
    Stem Cells Dev; 2019 Jun; 28(11):734-744. PubMed ID: 30585758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.